Fatty Liver News and Articles

Return to Library

Recent Fatty Liver News and Articles

• Scientists at University of Arizona College of Medicine Discuss Research in Endocrinology
• Study Findings from Digestive Disease Institute Provide New Insights into Fatty Liver
• Data from University of Paris Provide New Insights into Hepatocellular Cancer
• New Findings Reported from University of Cambridge Describe Advances in Life Science
• New Liver Cancer Data Have Been Reported by Investigators at Baylor University College of Medicine
• Researchers from Center for Cancer Research Describe Findings in Proinsulin
• Scientists at Methodist Hospital Research Institute Describe Research in Endocrinology
• Findings in Internal Medicine Reported from C.L. Bennett and Co-Researchers
• New Findings Reported from University of Texas Southwestern Medical Center Describe Advances in Biomedicine

---

Researchers at University of Salerno Have Published New Data on Liver Diseases

2013 JAN 21 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on Liver Diseases is the subject of a report. According to news originating from Salerno, Italy, by NewsRx correspondents, research stated, " The epidemics of overweight and obesity has resulted in a significant increase of non alcoholic fatty liver disease (NAFLD), a potentially progressive condition. Currently, obesity related hepatopathy represents therefore the main cause of pediatric chronic liver disease."

Our news journalists obtained a quote from the research from the University of Salerno, "The first choice treatment at all ages is weight loss and/or lifestyle changes, however compliance is very poor and a pharmacological approach has become necessary. In the present article we present a systematic literature review focusing on established pediatric NALFD drugs (ursodeoxycholic acid, insulin sensitizers, and antioxidants) and on innovative therapeutic options as well.Regarding the former ones, a pediatric pilot study highlighted that ursodeoxycholic acid is not efficient on transaminases levels and bright liver. Similarly, a recent large scale, multicenter randomized clinical trial (TONIC study) showed that also insulin sensitizers and antioxidant vitamin E have scarce effects on serum transaminase levels. Among a large series of novel therapeutic approaches acting on recently proposed different pathomechanisms, probiotics seem hitherto the most interesting and reasonable option for their safety and tolerability."

According to the news editors, the research concluded: "Toll-like receptors modifiers, Pentoxifylline, and Farnesoid X receptors agonists have been still poorly investigated, and will need further studies before becoming possible promising innovative therapeutic strategies."

For more information on this research see: Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Italian Journal of Pediatrics, 2012;38():55. (BioMed Central - www.biomedcentral.com/; Italian Journal of Pediatrics - www.ijponline.net)

The news correspondents report that additional information may be obtained from P. Vajro, Chair of Pediatrics, Medical School of the University of Salerno, Salerno, Italy and ELFID, Naples, Italy.

Keywords for this news article include: Italy, Europe, Salerno, Therapy, Pediatrics, Fatty Liver Disease, Alcoholic Fatty Liver, Digestive System Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC